Peptic Ulcer Disease and H. Pylori
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Peptic Ulcer Disease
Peptic Ulcer Disease orking with you as a partner in health care, your gastroenterologist Wat GI Associates will determine the best diagnostic and treatment measures for your unique needs. Albert F. Chiemprabha, M.D. Pierce D. Dotherow, M.D. Reed B. Hogan, M.D. James H. Johnston, III, M.D. Ronald P. Kotfila, M.D. Billy W. Long, M.D. Paul B. Milner, M.D. Michelle A. Petro, M.D. Vonda Reeves-Darby, M.D. Matt Runnels, M.D. James Q. Sones, II, M.D. April Ulmer, M.D., Pediatric GI James A. Underwood, Jr., M.D. Chad Wigington, D.O. Mark E. Wilson, M.D. Cindy Haden Wright, M.D. Keith Brown, M.D., Pathologist Samuel Hensley, M.D., Pathologist Jackson Madison Vicksburg 1421 N. State Street, Ste 203 104 Highland Way 1815 Mission 66 Jackson, MS 39202 Madison, MS 39110 Vicksburg, MS 39180 Telephone 601/355-1234 • Fax 601/352-4882 • 800/880-1231 www.msgastrodocs.com ©2010 GI Associates & Endoscopy Center. All rights reserved. A discovery that Table of contents brought relief to millions of ulcer What Is Peptic Ulcer Disease............... 2 patients...... Three Major Types Of Peptic Ulcer Disease .. 6 The bacterium now implicated as a cause of some ulcers How Are Ulcers Treated................... 9 was not noticed in the stomach until 1981. Before that, it was thought that bacteria couldn’t survive in the stomach because Questions & Answers About Peptic Ulcers .. 11 of the presence of acid. Australian pathologists, Drs. Warren and Marshall found differently when they noticed bacteria Ulcers Can Be Stubborn................... 13 while microscopically inspecting biopsies from stomach tissue. -
Potential of Bacterial Cellulose Chemisorbed with Anti-Metabolites, 3-Bromopyruvate Or Sertraline, to Fight Against Helicobacter Pylori Lawn Biofilm
International Journal of Molecular Sciences Article Potential of Bacterial Cellulose Chemisorbed with Anti-Metabolites, 3-Bromopyruvate or Sertraline, to Fight against Helicobacter pylori Lawn Biofilm Paweł Krzy˙zek 1,* , Gra˙zynaGo´sciniak 1 , Karol Fijałkowski 2 , Paweł Migdał 3 , Mariusz Dziadas 4 , Artur Owczarek 5 , Joanna Czajkowska 6, Olga Aniołek 7 and Adam Junka 8 1 Department of Microbiology, Faculty of Medicine, Wroclaw Medical University, 50-368 Wroclaw, Poland; [email protected] 2 Department of Immunology, Microbiology and Physiological Chemistry, Faculty of Biotechnology and Animal Husbandry, West Pomeranian University of Technology in Szczecin, 70-311 Szczecin, Poland; karol.fi[email protected] 3 Department of Environment, Hygiene and Animal Welfare, Wroclaw University of Environmental and Life Sciences, 51-630 Wroclaw, Poland; [email protected] 4 Faculty of Chemistry, University of Wroclaw, 50-353 Wroclaw, Poland; [email protected] 5 Department of Drug Form Technology, Wroclaw Medical University, 50-556 Wroclaw, Poland; [email protected] 6 Laboratory of Microbiology, Polish Center for Technology Development PORT, 54-066 Wroclaw, Poland; [email protected] 7 Faculty of Medicine, Lazarski University, 02-662 Warsaw, Poland; [email protected] 8 Department of Pharmaceutical Microbiology and Parasitology, Wroclaw Medical University, 50-556 Wroclaw, Poland; [email protected] * Correspondence: [email protected] Received: 23 November 2020; Accepted: 11 December 2020; Published: 14 December 2020 Abstract: Helicobacter pylori is a bacterium known mainly of its ability to cause persistent inflammations of the human stomach, resulting in peptic ulcer diseases and gastric cancers. Continuous exposure of this bacterium to antibiotics has resulted in high detection of multidrug-resistant strains and difficulties in obtaining a therapeutic effect. -
Helicobacter Pylori and Peptic Ulcers
Helicobacter pylori and Peptic Ulcers [Announcer] This podcast is presented by the Centers for Disease Control and Prevention. CDC – safer, healthier people. [Karen Hunter] Hello, I'm Karen Hunter. With me today is Dr. David Swerdlow, senior advisor for epidemiology in the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention. We’re talking about a paper that appears in the September 2010 issue of the CDC's journal, Emerging Infectious Diseases. The article looks at hospitalization rates for peptic ulcer disease in American patients who may have been infected with the bacteria Helicobacter pylori. Welcome, Dr. Swerdlow. [David Swerdlow] Thank you very much. [Karen Hunter] Dr. Swerdlow, what is Helicobacter pylori and how does it affect people? [David Swerdlow] Helicobacter pylori, or H. pylori for short, is a very common spiral-shaped bacteria that can colonize your stomach. It is estimated that about 50 percent of the world is infected, with most people becoming infected in childhood. Although the majority of people infected with H. pylori do not have any symptoms, infection with the bacteria can cause a variety of gastrointestinal diseases, including peptic ulcer disease and gastric cancers. The rate of infection with H. pylori is decreasing in most of the world, primarily because of improvements in hygiene and sanitation, but since infection is life-long, unless treated, many people are still at risk for peptic ulcer disease. [Karen Hunter] What is it about an infection with H. pylori that increases the risk of developing peptic ulcer disease? [David Swerdlow] H. pylori can colonize and damage the protective lining of your stomach and create chronic inflammation. -
Abdominal Pain - Gastroesophageal Reflux Disease
ACS/ASE Medical Student Core Curriculum Abdominal Pain - Gastroesophageal Reflux Disease ABDOMINAL PAIN - GASTROESOPHAGEAL REFLUX DISEASE Epidemiology and Pathophysiology Gastroesophageal reflux disease (GERD) is one of the most commonly encountered benign foregut disorders. Approximately 20-40% of adults in the United States experience chronic GERD symptoms, and these rates are rising rapidly. GERD is the most common gastrointestinal-related disorder that is managed in outpatient primary care clinics. GERD is defined as a condition which develops when stomach contents reflux into the esophagus causing bothersome symptoms and/or complications. Mechanical failure of the antireflux mechanism is considered the cause of GERD. Mechanical failure can be secondary to functional defects of the lower esophageal sphincter or anatomic defects that result from a hiatal or paraesophageal hernia. These defects can include widening of the diaphragmatic hiatus, disturbance of the angle of His, loss of the gastroesophageal flap valve, displacement of lower esophageal sphincter into the chest, and/or failure of the phrenoesophageal membrane. Symptoms, however, can be accentuated by a variety of factors including dietary habits, eating behaviors, obesity, pregnancy, medications, delayed gastric emptying, altered esophageal mucosal resistance, and/or impaired esophageal clearance. Signs and Symptoms Typical GERD symptoms include heartburn, regurgitation, dysphagia, excessive eructation, and epigastric pain. Patients can also present with extra-esophageal symptoms including cough, hoarse voice, sore throat, and/or globus. GERD can present with a wide spectrum of disease severity ranging from mild, intermittent symptoms to severe, daily symptoms with associated esophageal and/or airway damage. For example, severe GERD can contribute to shortness of breath, worsening asthma, and/or recurrent aspiration pneumonia. -
American Cancer Society Flufobt Program Implementation Guide for Primary Care Practices
Health Care Solutions From the American Cancer Society American Cancer Society FluFOBT Program Implementation Guide for Primary Care Practices EIGHTY BY 2018 Reaching 80% screened for colorectal cancer by 2018 Table of Contents Introduction ................................................................................................................................. 2 Background Information and Education .................................................................................... 3 Why Have a FluFOBT Program? .................................................................................................. 4 Colorectal Cancer Screening Eligibility ...................................................................................... 5 Colorectal Cancer Screening Recommendations ....................................................................... 6 Patient Education ......................................................................................................................... 8 How to Set Up Your FluFOBT Program .................................................................................... 10 Staff Training for Your FluFOBT Program ................................................................................ 16 Summary ..................................................................................................................................... 19 Appendix A: FluFOBT Components and Logic Model ............................................................ 20 Appendix B: Colorectal Cancer Screening Recommendations -
Gastroenteritis and Transmission of Helicobacter Pylori Infection in Households1 Sharon Perry,* Maria De La Luz Sanchez,* Shufang Yang,* Thomas D
Gastroenteritis and Transmission of Helicobacter pylori Infection in Households1 Sharon Perry,* Maria de la Luz Sanchez,* Shufang Yang,* Thomas D. Haggerty,* Philip Hurst,† Guillermo Perez-Perez,‡ and Julie Parsonnet* The mode of transmission of Helicobacter pylori gastrointestinal infections, infection is associated with infection is poorly characterized. In northern California, conditions of crowding and poor hygiene (7,8) and with 2,752 household members were tested for H. pylori infec- intrafamilial clustering (9–12). The organism has been tion in serum or stool at a baseline visit and 3 months later. recovered most reliably from vomitus and from stools dur- Among 1,752 person considered uninfected at baseline, ing rapid gastrointestinal transit (13). These findings raise 30 new infections (7 definite, 7 probable, and 16 possible) occurred, for an annual incidence of 7% overall and 21% the hypothesis that gastroenteritis episodes provide the in children <2 years of age. Exposure to an infected opportunity for H. pylori transmission. household member with gastroenteritis was associated Household transmission of gastroenteritis is common in with a 4.8-fold (95% confidence interval [CI] 1.4–17.1) the United States, particularly in homes with small chil- increased risk for definite or probable new infection, with dren (14). If H. pylori is transmitted person to person, one vomiting a greater risk factor (adjusted odds ratio [AOR] might expect rates of new infection to be elevated after 6.3, CI 1.6–24.5) than diarrhea only (AOR 3.0, p = 0.65). exposure to persons with H. pylori–infected cases of gas- Of probable or definite new infections, 75% were attributa- troenteritis. -
(NCCN Guidelines®) Colorectal Cancer Screening
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colorectal Cancer Screening Version 2.2017 — November 14, 2017 NCCN.org Continue Version 2.2017, 11/14/17 © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN® NCCN Guidelines Version 2.2017 Panel Members NCCN Guidelines Index Table of Contents Colorectal Cancer Screening Discussion * Dawn Provenzale, MD, MS/Chair ¤ Þ Michael J. Hall, MD, MS † ∆ Robert J. Mayer, MD † Þ Duke Cancer Institute Fox Chase Cancer Center Dana-Farber/Brigham and Women’s Cancer Center * Samir Gupta, MD/Vice-chair ¤ Amy L. Halverson, MD ¶ UC San Diego Moores Cancer Center Robert H. Lurie Comprehensive Cancer Reid M. Ness, MD, MPH ¤ Center of Northwestern University Vanderbilt-Ingram Cancer Center Dennis J. Ahnen, MD ¤ University of Colorado Cancer Center Stanley R. Hamilton, MD ≠ Scott E. Regenbogen, MD ¶ The University of Texas University of Michigan Travis Bray, PhD ¥ MD Anderson Cancer Center Comprehensive Cancer Center Hereditary Colon Cancer Foundation Heather Hampel, MS, CGC ∆ Niloy Jewel Samadder, MD ¤ Daniel C. Chung, MD ¤ ∆ The Ohio State University Comprehensive Huntsman Cancer Institute at the Massachusetts General Hospital Cancer Center - James Cancer Hospital University of Utah Cancer Center and Solove Research Institute Moshe Shike, MD ¤ Þ Gregory Cooper, MD ¤ Jason B. Klapman, MD ¤ Memorial Sloan Kettering Cancer Center Case Comprehensive Cancer Center/ Moffitt Cancer Center University Hospitals Seidman Cancer Thomas P. Slavin Jr, MD ∆ Center and Cleveland Clinic Taussig David W. Larson, MD, MBA¶ City of Hope Comprehensive Cancer Institute Mayo Clinic Cancer Center Cancer Center Dayna S. -
High Quality Fecal Occult Blood Testing (FOBT) for CRC Screening: Evidence and Recommendations
High Quality Fecal Occult Blood Testing (FOBT) for CRC Screening: Evidence and Recommendations Rationale for use of FOBT High sensitivity fecal occult blood testing (FOBT) is one of the colorectal cancer screening methods recommended in guidelines from the American Cancer Society, the US Preventive Services Taskforce, and every other major medical organization. In spite of this widespread endorsement, primary care clinicians often express conviction that colonoscopy is the “gold standard” test for colorectal cancer screening and that the use of FOBT represents sub-standard care. These beliefs persist in spite of well-documented shortcomings of endoscopy (missed adenomas and cancers, higher complication rates and higher one-time costs than other screening methodologies), and the fact that access to endoscopy is limited or non- existent for a significant proportion of the U.S. population. Many clinicians are also unaware that randomized controlled trials of FOBT screening have demonstrated decreases in colorectal cancer incidence and mortality, and modeling studies suggest that the years of life saved through a high quality FOBT screening program are essentially the same as with a high quality colonoscopy based screening programs. Recent advances in stool blood screening include the emergence of new tests and improved understanding of the impact of quality factors on testing outcomes. This document provides state-of-the-science information about high quality stool testing. Types of Fecal Occult Blood Tests Two main types of FOBT are available – guaiac and immunochemical. Both types of FOBT have been shown to have reasonably high detection rates for colon and rectal cancers; adenoma detection rates are appreciably lower. -
Active Peptic Ulcer Disease in Patients with Hepatitis C Virus-Related Cirrhosis: the Role of Helicobacter Pylori Infection and Portal Hypertensive Gastropathy
dore.qxd 7/19/2004 11:24 AM Page 521 View metadata, citation and similar papers at core.ac.uk ORIGINAL ARTICLE brought to you by CORE provided by Crossref Active peptic ulcer disease in patients with hepatitis C virus-related cirrhosis: The role of Helicobacter pylori infection and portal hypertensive gastropathy Maria Pina Dore MD PhD, Daniela Mura MD, Stefania Deledda MD, Emmanouil Maragkoudakis MD, Antonella Pironti MD, Giuseppe Realdi MD MP Dore, D Mura, S Deledda, E Maragkoudakis, Ulcère gastroduodénal évolutif chez les A Pironti, G Realdi. Active peptic ulcer disease in patients patients atteints de cirrhose liée au HCV : Le with hepatitis C virus-related cirrhosis: The role of Helicobacter pylori infection and portal hypertensive rôle de l’infection à Helicobacter pylori et de la gastropathy. Can J Gastroenterol 2004;18(8):521-524. gastropathie liée à l’hypertension portale BACKGROUND & AIM: The relationship between Helicobacter HISTORIQUE ET BUT : Le lien entre l’infection à Helicobacter pylori pylori infection and peptic ulcer disease in cirrhosis remains contro- et l’ulcère gastroduodénal dans la cirrhose reste controversé. Le but de la versial. The purpose of the present study was to investigate the role of présente étude est de vérifier le rôle de l’infection à H. pylori et de la gas- H pylori infection and portal hypertension gastropathy in the preva- tropathie liée à l’hypertension portale dans la prévalence de l’ulcère gas- lence of active peptic ulcer among dyspeptic patients with compen- troduodénal évolutif chez les patients dyspeptiques souffrant d’une sated hepatitis C virus (HCV)-related cirrhosis. -
Challenges in the Management of Acute Peptic Ulcer Bleeding
Review Challenges in the management of acute peptic ulcer bleeding James Y W Lau, Alan Barkun, Dai-ming Fan, Ernst J Kuipers, Yun-sheng Yang, Francis K L Chan Acute upper gastrointestinal bleeding is a common medical emergency worldwide, a major cause of which are bleeding Lancet 2013; 381: 2033–43 peptic ulcers. Endoscopic treatment and acid suppression with proton-pump inhibitors are cornerstones in the Institute of Digestive Diseases, management of the disease, and both treatments have been shown to reduce mortality. The role of emergency surgery The Chinese University of Hong continues to diminish. In specialised centres, radiological intervention is increasingly used in patients with severe and Kong, Hong Kong, China (Prof J Y W Lau MD, recurrent bleeding who do not respond to endoscopic treatment. Despite these advances, mortality from the disorder Prof F K L Chan MD); Division of has remained at around 10%. The disease often occurs in elderly patients with frequent comorbidities who use Gastroenterology, McGill antiplatelet agents, non-steroidal anti-infl ammatory drugs, and anticoagulants. The management of such patients, University and the McGill especially those at high cardiothrombotic risk who are on anticoagulants, is a challenge for clinicians. We summarise University Health Centre, Quebec, Canada the published scientifi c literature about the management of patients with bleeding peptic ulcers, identify directions for (Prof A Barkun MD); Institute of future clinical research, and suggest how mortality can be reduced. Digestive Diseases, Xijing Hospital, Fourth Military Introduction by how participants were sampled, their inclusion Medical University, Xian, China (Prof D Fan MD); Department of Acute upper gastrointestinal bleeding is characterised by criteria, and defi nitions of case ascertainment. -
Helicobacter Heilmannii Associated Erosive Gastritis
CASE REPORT Helicobacter heilmannii Associated Erosive Gastritis Takafumi Yamamoto, Jun Matsumoto, Ken Shiota, Shin-ichi Kitajima*, Masamichi Goto*, Masaomi Imaizumi* and Terukatsu Arima The spiral bacteria, Helicobacter heilmannii (H heilmannii), distinct from Helicobacterpylori (H. pylori), was found in the gastric mucosa of a 71-year-old manwithout clinical symptoms. The endoscopic examination revealed erosive gastritis. Rapid urease test from the antral specimen was positive, but both culture and immunohistological staining for Hpylori were negative. Touch smear cytology showedtightly spiral bacteria, which were consistent with H.heilmannii. At the second endoscopy after medication regimen for eradication of H. pylori, inflammation was decreased and the rapid urease test was negative. The second cytology showedno evidence of Hheilmannii. Anti-H.pylori therapy may be a useful medication for H.heilmannii. (Internal Medicine 38: 240-243, 1999) Keywords: gastric spiral bacteria, touch smear cytology, eradication Introduction previously been healthy. He had a clinical history of Hansen's disease (leprosy). His family history was noncontributory. He Since 1983 when Warren and Marshall (1) first described reported no history of smoking or alcohol, but earlier had a pet Helicohacterpylori (H.pylori) and its association with chronic cat. Neither anemia nor jaundice was present. Abdomenwas gastritis, there have been manyreports of microbiological and flat and soft. Liver, spleen and mass were not palpable. Labo- clinical studies about H.pylori infection. It has been generally ratory data of our clinic waswithin the normal range. Serum accepted that H.pylori infection causes atrophic gastritis, gas- anti-H.pylori immunoglobulin G (IgG) antibody (HELICO-G) tric ulcer and duodenal ulcer. -
Comparative Analysis of Four Campylobacterales
REVIEWS COMPARATIVE ANALYSIS OF FOUR CAMPYLOBACTERALES Mark Eppinger*§,Claudia Baar*§,Guenter Raddatz*, Daniel H. Huson‡ and Stephan C. Schuster* Abstract | Comparative genome analysis can be used to identify species-specific genes and gene clusters, and analysis of these genes can give an insight into the mechanisms involved in a specific bacteria–host interaction. Comparative analysis can also provide important information on the genome dynamics and degree of recombination in a particular species. This article describes the comparative genomic analysis of representatives of four different Campylobacterales species — two pathogens of humans, Helicobacter pylori and Campylobacter jejuni, as well as Helicobacter hepaticus, which is associated with liver cancer in rodents and the non-pathogenic commensal species, Wolinella succinogenes. ε CHEMOLITHOTROPHIC The -subdivision of the Proteobacteria is a large group infection can lead to gastric cancer in humans 9–11 An organism that is capable of of CHEMOLITHOTROPHIC and CHEMOORGANOTROPHIC microor- and liver cancer in rodents, respectively .The using CO, CO2 or carbonates as ganisms with diverse metabolic capabilities that colo- Campylobacter representative C. jejuni is one of the the sole source of carbon for cell nize a broad spectrum of ecological habitats. main causes of bacterial food-borne illness world- biosynthesis, and that derives Representatives of the ε-subgroup can be found in wide, causing acute gastroenteritis, and is also energy from the oxidation of reduced inorganic or organic extreme marine and terrestrial environments ranging the most common microbial antecedent of compounds. from oceanic hydrothermal vents to sulphidic cave Guillain–Barré syndrome12–15.Besides their patho- springs. Although some members are free-living, others genic potential in humans, C.